Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of Monoclonal Antibody to OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer After Systemic Therapy

NCT01303705 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT01303705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01303705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of Monoclonal Antibody to OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer After Systemic Therapy
Lead sponsor
Providence Health & Services
Phase
Phase 1
Overall status
Completed
Start date
October 14, 2010
Completion date
July 5, 2016
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of the prostate, metastatic prostate cancer, prostate cancer